BioCentury | Dec 12, 2020
Translation in Brief

Fecal transplant improves checkpoint inhibitor response in Phase I; plus Secarna’s antitumor antisense oligos, a blood-based mRNA test for Alzheimer’s and more

...species with CTLA-4 or PD-L1 blockade.Secarna’s antisense oligo prevents tumor progressionSecarna Pharmaceuticals GmbH reported that its MTDH-targeting...
...CD152) – Cytotoxic T-lymphocyte associated protein 4 HPGD (15-PGDH) – Hydroxyprostaglandin dehydrogenase 15 NAD MTDH (AEG1) – Metadherin PD-1...
...Golovin Secarna Pharmaceuticals GmbH Princeton University Firebrand Therapeutics Inc. Stanford University Tel Aviv University Molecular Stethoscope Inc. National Institutes of Health Metadherin (MTDH) (AEG1) Hydroxyprostaglandin...
BioCentury | Sep 25, 2014
Distillery Techniques

Technology: Imaging

...metadherin (MTDH; AEG1) promoter to image prostate cancer A nanoparticle-based imaging system that uses the AEG1...
...for intracellular delivery of a construct encoding a luciferase gene controlled by the cancer cell-associated AEG1...
BioCentury | Dec 17, 2012
Company News

Pharmascience, GlaxoSmithKline deal

Pharmascience and Human Genome Sciences Inc. mutually terminated a 2007 deal granting Human Genome ex-Japanese rights to HGS1029 ( AEG40826 ). Pharmascience, which regains worldwide rights to the small molecule antagonist against inhibitor of apoptosis (IAP)...
BioCentury | Jan 16, 2012
Company News

Human Genome Sciences autoimmune, cancer news

Human Genome said it will reduce headcount by 101 (8%) to about 1,200. The cuts will come from manufacturing, R&D and administration. Benlysta belimumab, a human mAb against BLyS (B lymphocyte stimulator protein), is approved...
BioCentury | Jan 16, 2012
Clinical News

HGS1029: Development halted

Human Genome said it halted development of HGS1029. The compound was in Phase I testing for advanced solid and advanced lymphoid tumors. Details were not disclosed. Human Genome has ex-Japanese rights to HGS1029 from Aegera...
BioCentury | Jun 6, 2011
Company News

Aegera, Pharmascience deal

Generics company Pharmascience acquired cancer company Aegera. Pharmascience said the acquisition will diversify its R&D activities. Aegera's pipeline include AEG35156 , a second-generation antisense X-linked inhibitor of apoptosis protein ( XIAP ) mRNA in Phase II testing to...
BioCentury | Sep 20, 2010
Emerging Company Profile

Calithera: Activating Caspases

Unlike most companies working on inducing apoptosis to treat cancer, which have focused on upstream components of the pathway, Calithera Biosciences Inc. has identified small molecules that work far downstream to activate caspases . The company...
BioCentury | Feb 1, 2010
Clinical News

AEG35156: Phase II started

Aegera began an open-label, Hong Kong Phase II trial to evaluate Nexavar sorafenib with or without AEG35156 in 50 patients. Bayer AG (Xetra:BAY, Leverkusen, Germany) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX, Emeryville, Calif.) market Nexavar to...
BioCentury | Dec 7, 2009
Clinical News

HGS1029: Phase I started

Human Genome began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous HGS1029 given once weekly for 3 weeks followed by 1 week off. The company has ex-Japanese rights for HGS1029 and related compounds...
BioCentury | Dec 7, 2009
Clinical News

AEG35156: Phase IIb started

Aegera began an open-label, international Phase IIb trial to evaluate cytarabine and idarubicin with or without 350 mg/m 2 intravenous AEG35156 in 60 patients who did not respond to standard cytarabine therapy. Aegera Therapeutics Inc....
Items per page:
1 - 10 of 34